Who Paid My Doc
Ivan Zendejas Ruiz
Surgery Murray, UT Medical Doctor
NPI 1760542054 CMS profile 1125487
5171 S Cottonwood St, Ste 650, Murray, UT 84107
General payments
$35,593
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$324,963
Through program year 2025, Ivan Zendejas Ruiz of Murray, UT is reported in the CMS Open Payments database as having received $35,593 across 178 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $324,963 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,373 | 26 | |
| 2024 | General | $7,046 | 39 | |
| 2023 | General | $2,458 | 24 | |
| 2022 | General | $282 | 16 | |
| 2021 | General | $842 | 18 | |
| 2020 | General | $9,700 | 25 | |
| 2019 | General | $6,893 | 30 |
Beside peers
- Ivan Zendejas Ruiz
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Ivan Zendejas Ruiz were reported at $8,373. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Ivan Zendejas Ruiz | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $6,893 | $253 | $82–$1,521 | $163 |
| 2020 | $9,700 | $131 | $40–$706 | $114 |
| 2021 | $842 | $168 | $50–$904 | $132 |
| 2022 | $282 | $224 | $76–$1,218 | $149 |
| 2023 | $2,458 | $253 | $82–$1,255 | $160 |
| 2024 | $7,046 | $279 | $90–$1,381 | $164 |
| 2025 | $8,373 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
54
Drug cost
$2,208
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ursodiol | Generic | 29 | $2,030 | |
| Oxycodone Hcl | Generic | 11 | $107 | |
| Pantoprazole Sodium | Generic | 14 | $71 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 69 billing codesPaid by Medicare
$177,858
Medicare patients
151
Services billed
438
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 58% | |
| Diabetes | 54% | |
| Ischemic heart disease | 36% | |
| Arthritis | 36% | |
| Depression | 24% | |
| Cancer | 23% | |
| Heart failure | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
178 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in Utah
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.